This week, a number of companies, big and small, shared updates on their cardiovascular technology innovations at EuroPCR ...

MILPITAS, Calif., March 18, 2025--(BUSINESS WIRE)--Elixir Medical is proud to have been named to Fast Company’s prestigious list of the World’s Most Innovative Companies of 2025. This year’s ...

Elixir Medical announced three-year results from a large randomized controlled trial of its DynamX coronary bioadaptor system.

Elixir Medical has joined the growing intravascular lithotripsy (IVL) market following the CE marking of its LithiX Hertz Contact system. The LithiX device employs focal stress contact points to ...

MILPITAS, Calif., April 10, 2025 (GLOBE NEWSWIRE) -- Elixir Medical, a developer of disruptive technologies to treat cardiovascular disease, today announced EU MDR CE Mark approval and commercial ...

Given IVL’s promise, many companies have emerged with their own IVL approach. US-based Elixir Medical is one such company, gaining European approval for its LithiX Hertz device in April 2025.

Clinical follow-up will continue through five years. BIOADAPTOR RCT trial is the third trial of Elixir Medical’s robust DynamX® bioadaptor clinical evidence program consisting of nine company ...

In search of a better solution than stents, Elixir Medical has developed the DynamX, which has three helical strands linked together. It is coated in a biodegradable polymer that releases a ...

MILPITAS, Calif., March 18, 2025--(BUSINESS WIRE)--Elixir Medical is proud to have been named to Fast Company’s prestigious list of the World’s Most Innovative Companies of 2025. This year’s list ...

BIOADAPTOR RCT trial is the third trial of Elixir Medical’s robust DynamX ® bioadaptor clinical evidence program consisting of nine company-sponsored and investigator-initiated studies ...